drugset / Trial / NCT00073593
Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
Timeline
- Start
- 2003-08
- Primary completion
- 2004-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bivalirudin | Peptide | 1.75 mg/kg | Intravenous |
| Comparator | Heparin | Other / unclassified | 1.5 mg/kg | Intravenous |
| Comparator | Heparin | Other / unclassified | 3.5 mg/kg | Intravenous |
| Comparator | Heparin | Other / unclassified | 200 iu/kg | Intravenous |
| Comparator | Heparin | Other / unclassified | 400 iu/kg | Intravenous |
| Comparator | Protamine Sulfate | Unknown | — | — |